^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

TNFRSF8 positive

i
Other names: TNFRSF8, TNF Receptor Superfamily Member 8, Tumor Necrosis Factor Receptor Superfamily Member 8, Lymphocyte Activation Antigen CD30, CD30L Receptor, Ki-1 Antigen, D1S166E, CD30, Tumor Necrosis Factor Receptor Superfamily, Member 8, Cytokine Receptor CD30, CD30 Antigen, TNFRSF8, Ki-1
Entrez ID:
Related biomarkers:
8d
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov)
P2, N=46, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> Mar 2024 | Trial primary completion date: Sep 2025 --> Mar 2024
Trial completion • Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin)
11d
Trial completion
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Opdivo (nivolumab) • cabiralizumab (BMS-986227)
17d
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery (clinicaltrials.gov)
P2, N=55, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
Trial completion date • Trial primary completion date • Surgery
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive • TNFRSF8 expression
|
Adcetris (brentuximab vedotin)
1m
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc (clinicaltrials.gov)
P2, N=11, Recruiting, Lawson Health Research Institute | Not yet recruiting --> Recruiting | Trial completion date: Mar 2026 --> Jul 2026 | Trial primary completion date: Nov 2025 --> Feb 2026
Enrollment open • Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • IL2 (Interleukin 2)
|
TNFRSF8 positive
|
cyclophosphamide • Adcetris (brentuximab vedotin)
1m
Clinicopathologic features and survival outcomes of CD30 expression in extranodal natural killer/T-cell lymphoma. (PubMed, Am J Clin Pathol)
Positive CD30 expression was a favorable prognostic factor for ENKTL, and CD30 expression could restratify the survival of patients in clinical subgroups.
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive • TNFRSF8 expression
1m
Anaplastic large cell lymphoma presenting as a mass in the uterine cervix: a case report. (PubMed, J Hematop)
Since ALCL may have a variable expression of T-cell antigens, the diagnosis may easily be missed when CD45 and/or CD3 is negative, and screening epithelial stains for carcinoma (e.g., p63 and EMA) are positive. CD30 must be performed to raise the consideration of ALCL when reniform nuclei are observed.
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • TP63 (Tumor protein 63)
|
ALK rearrangement • TNFRSF8 positive • TNFRSF8 expression
1m
Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis. (PubMed, Am J Clin Pathol)
Flow cytometric immunophenotyping is a quick, sensitive, high-yield tool for evaluating the immunophenotype of mast cells. An abnormal FCI finding should prompt careful histologic evaluation and sensitive KIT D816V mutation testing to address the possibility of SM. CD2, CD25, and CD30 are important markers for the detection of immunophenotypic aberrancy of mast cells, and their frequencies of aberrancy differ across SM subtypes.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • IL2RA (Interleukin 2 receptor, alpha) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD2 (CD2 Molecule) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
|
TNFRSF8 positive • TNFRSF8 expression • KIT D816V
1m
P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov)
P2, N=48, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 positive • ALK negative
|
doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • daunorubicin
1m
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies (clinicaltrials.gov)
P1, N=20, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=30 --> 20
Enrollment closed • Enrollment change
|
TNFRSF8 positive
|
lenalidomide • Istodax (romidepsin) • Onureg (azacitidine oral)
1m
Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy. (PubMed, Virchows Arch)
In conclusion, 44% of ALCL patients, regardless of histological subtypes, showed a loss of/decrease in CD30 expression after receiving BV-containing therapy, but this phenomenon was not observed in CHL patients. A higher cumulative dose of BV and a lower amount of CD30 antigen in tumor cells in the initial biopsy materials might be predictors of a loss of/decrease in CD30 expression in ALCL patients.
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 positive • TNFRSF8 expression • ALK negative
|
Adcetris (brentuximab vedotin)
2ms
Primary Cutaneous CD30-Positive Lymphoproliferative Disorders-Current Therapeutic Approaches with a Focus on Brentuximab Vedotin. (PubMed, J Clin Med)
Recent years have seen the introduction of novel agents into clinical practice; most of these target CD30, such as anti-CD30 monoclonal antibodies and conjugated antibodies (brentuximab vedotin), bispecific antibodies and cellular therapies, particularly anti-CD30 CAR-T cells. This paper briefly reviews the biology of CD30 that makes it a good therapeutic target and describes the anti-CD30 therapies that have emerged to date.
Review • Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin)
2ms
Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs). (PubMed, Blood)
These entities are currently treated similarly with CHOP or CHOEP for CD30-negative diseases or brentuximab vedotin plus CHP for CD30-positive diseases, followed by consolidation with autologous stem cell transplant in first remission...Although current treatment strategies lump most disease entities together, future treatment will include distinct strategies for each disease subtype that optimizes therapy for individuals. This movement towards individualized therapy will ultimately lead to dramatic improvements in prognosis for patients with PTCL.
Journal
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive • TNFRSF8 negative
|
Adcetris (brentuximab vedotin)
2ms
Trial completion
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
acimtamig (AFM13)
2ms
EBV-positive Nodal T-Cell and NK-Cell Lymphoma: A Study of 26 Cases Including a Subset With Strong CD30 Expression Mimicking Anaplastic Large Cell Lymphoma. (PubMed, Am J Surg Pathol)
Distinguishing between EBV+ nodal T-cell and NK-cell lymphoma from ALCL is important because treatment strategy and prognosis differ. CD30 expression offers a potential therapeutic target for patients with this aggressive disease.
Journal
|
CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
|
TNFRSF8 positive • TNFRSF8 expression
2ms
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov)
P2, N=23, Recruiting, Joseph Tuscano | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin) • bendamustine
2ms
Trial completion
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin)
3ms
Primary leptomeningeal CD30 positive diffuse large B cell lymphoma disguise as meningioma in a young adult. (PubMed, Int J Neurosci)
PLMLs usually present in the elderly with a short duration of illness. Herein, we describe a case of CD30 positive diffuse large B-cell PLML in a young 21-years-old male with review of literature.
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
3ms
CD30 protects EBV-positive diffuse large B-cell lymphoma cells against mitochondrial dysfunction through BNIP3-mediated mitophagy. (PubMed, Cancer Lett)
Additionally, CRISPR BNIP3 knockout caused proliferation defects and increased sensitivity to apoptosis. All the findings reveal a strong relationship between mitophagy and adverse prognosis of EBV DLBCL and discover a new regulatory mechanism of BNIP3-mediated mitophagy, which may help develop effective treatment regimens with anti-CD30 antibody brentuximab vedotin to improve the prognosis of CD30 EBV DLBCL patients.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BNIP3 (BCL2 Interacting Protein 3)
|
TNFRSF8 positive • TNFRSF8 expression
|
Adcetris (brentuximab vedotin)
3ms
A Mouse Model to Study the Pathogenesis of γ-herpesviral Infections in Germinal Center B Cells. (PubMed, Cells)
While the LMP2A-expressing MHV-68 behaved similarly to wildtype MHV-68, virally induced constitutively active CD30-signaling in GC B cells led to the expansion of a pre-plasmablastic population. The findings underscore the potential of our novel tools to address crucial questions about the interaction between herpesviral infections and deregulated cellular gene-expression in future studies.
Preclinical • Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
3ms
Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review. (PubMed, Cancers (Basel))
In recent years, targeted therapies such as ALK inhibitors and brentuximab vedotin (BV) have been developed. Weekly vinblastine treatment and hematopoietic stem cell transplantation have also been reported to be effective therapies. This article reviews pediatric ALK-positive ALCL, focusing on risk factors and treatment strategies for pediatric patients with relapsed or refractory ALK-positive ALCL.
Review • Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • ALK mutation • TNFRSF8 positive • TNFRSF8 expression
|
Adcetris (brentuximab vedotin) • vinblastine
4ms
CD30 plays a role in T-dependent immune response and T cell proliferation. (PubMed, FASEB J)
High-throughput RNA sequencing analysis revealed that CD30 deficiency led to a decrease of FOXO-autophagy axis in T cells upon TCR stimulation. Thus, CD30 positively regulates T-cell-dependent immune response and T cell proliferation.
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • TNFA (Tumor Necrosis Factor-Alpha)
|
TNFRSF8 positive • TNFRSF8 expression
4ms
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1/2, N=240, Recruiting, Genmab | Trial completion date: Jun 2028 --> Dec 2032
Trial completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
GEN3017
4ms
Characteristics and Prognosis of Epstein Barr Virus-Positive Diffuse Large B-Cell Lymphoma: A Retrospective, Single-Center Study (ASH 2023)
After treatment with rituximab combined with chemotherapy, the EBV+DLBCL patients had a complete response rate and a overall response rate of 55... The majority of EBV+DLBCL patients were non-GCB. β2-Microglobulin level and bone marrow invasion were independent risk factors for PFS in patients with EBV+DLBCL, while β2-Microglobulin and HB were independent risk factors for OS in patients with EBV+DLBCL. The therapeutical potentials of targeted medicines, such as CD30 inhibitors and PD-1 inhibitors, deserve to be explored in the future.
Retrospective data
|
B2M (Beta-2-microglobulin)
|
TNFRSF8 positive
|
Rituxan (rituximab)
4ms
Combining BCL-XL Inhibition with Brentuximab Vedotin to Overcome Chemoresistance in EBV-Related T/NK Lymphoma (ASH 2023)
MethodsA diverse panel of EBV+ T/NK lymphoma cell lines including SNK1, MECO4, SNK6, SNT8, SNK10, SNT15 and SNT16 were evaluated for sensitivity to MMAE alone and with specific BH3 family inhibitors including A1331852, inhibiting BCL-XL, venetoclax inhibiting and BCL-2 and the MCL-1 inhibitor S63845 (Generon). These data show the potential of BV with BCL-XL inhibition to be an effective and tolerable treatment for ENKTL. We are now planning a detailed preclinical study to better understand the efficacy and safety of this combination in vivo and progress towards a future clinical trial.
IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL2L1 (BCL2-like 1)
|
TNFRSF8 positive • TNFRSF8 expression
|
Venclexta (venetoclax) • Adcetris (brentuximab vedotin) • S63845 • A-1331852
4ms
Extracellular CD30 and ADAM10/17 Regulate Brentuximab Vedotin-Induced Cell Death in an Adult T-Cell Leukemia Cell Line (ASH 2023)
Moreover, endogenous extracellular CD30, such as sCD30 shed by ADAM10/17, and CD30-positive EVs may be responsible for the BV-induced cell death. Correctively, extracellular CD30 concentrations, including EV, may be useful as biomarkers for BV therapy in ATL.
Preclinical
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • ADAM10 (ADAM Metallopeptidase Domain 10)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin)
4ms
A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma (clinicaltrials.gov)
P=N/A, N=8, Recruiting, Takeda | Trial completion date: Jul 2027 --> Dec 2027 | Trial primary completion date: Jul 2027 --> Dec 2027
Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
doxorubicin hydrochloride • Adcetris (brentuximab vedotin)
4ms
Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma" (clinicaltrials.gov)
P=N/A, N=113, Completed, Takeda | Trial completion date: Dec 2022 --> Sep 2023 | Trial primary completion date: Dec 2022 --> Sep 2023
Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin)
4ms
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma" (clinicaltrials.gov)
P=N/A, N=95, Active, not recruiting, Takeda | Completed --> Active, not recruiting | Trial completion date: Sep 2023 --> Dec 2023
Enrollment closed • Trial completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin)
4ms
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK rearrangement • TNFRSF8 positive
4ms
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study. (PubMed, Blood Res)
The most common side effect of BV was peripheral neuropathy; 22 patients (25.9%, 22/85) experienced peripheral neuropathy (all grades). s : The treatment outcomes of patients with relapsed or refractory CD30-positive lymphoma improved with BV treatment, and the safety profile was manageable.
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin)
4ms
Primary cutaneous CD30+ lymphoproliferative disorders with DUSP22 translocation. (PubMed, Pathologie (Heidelb))
In cutaneous biopsies, both primary cutaneous DUSP22-translocated ALCL and LyP with DUSP22 rearrangements are characterized by a biphasic pattern with significant small cell epidermotropism. A distinct protein expression profile with preserved T Cell Receptor (TCR) expression, positivity for CD30, LEF1, HLA, and CD58, and negativity for cytotoxic marker expression as well as phospho-STAT3 protein is consistently found in these cases.
Review • Journal • IO biomarker
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD58 (CD58 Molecule) • DUSP22 (Dual Specificity Phosphatase 22) • USP22 (Ubiquitin Specific Peptidase 22)
|
TNFRSF8 positive • TNFRSF8 expression
4ms
Differential expression of BCL11b and CDKN2A in CD30-positive peripheral T cell lymphoma: Retrospective study. (PubMed, Medicine (Baltimore))
These results indicate that BCL11b may be involved in CD30 differentiation and PTCL prognosis. The detection and targeting of BCL11b and CD30 may provide new strategies for the treatment and classification of PTCL.
Retrospective data • Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL11B (BAF Chromatin Remodeling Complex Subunit BCL11B)
|
TNFRSF8 positive • TNFRSF8 expression • TNFRSF8 negative • CDKN2A expression
4ms
DUSP22-IRF4 Rearranged CD30-Positive Primary Cutaneous Lymphoproliferative Disorder With Gamma/Delta Phenotype. (PubMed, Am J Dermatopathol)
We hereby present an extraordinary case of CD30+PCLPD with DUSP22-IRF4 rearrangement and novel expression of gamma/delta T-cell immunophenotype in a young patient. Although the gamma/delta T-cell immunophenotype has been described in many other T-cell lymphomas, this is the first reported association with CD30+PCLPD with DUSP22-IRF4 rearrangement.
Journal • IO biomarker
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • IRF4 (Interferon regulatory factor 4) • DUSP22 (Dual Specificity Phosphatase 22) • USP22 (Ubiquitin Specific Peptidase 22)
|
TNFRSF8 positive
4ms
Epstein-Barr Virus-Associated Lymphomatoid Papules: A Sign of Immunosuppression Resembling Lymphomatoid Papulosis. (PubMed, Am J Dermatopathol)
Various treatment strategies were used, including observation (n = 3), discontinuation/reduction of immunosuppression (n = 3), rituximab (n = 4), and steroids (n = 4)...These cases suggest clinicopathologic presentations resembling lymphomatoid papulosis with atypical, large CD30-positive, EBV-positive cells could comprise first sign of potentially serious immunodeficiency and should prompt evaluation for EBV viremia. These cases also broaden the current picture of immunodeficiency-associated lymphoproliferative disorders to include lymphomatoid papulosis-like clinical presentations.
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Rituxan (rituximab)
4ms
Extranodal NK/T-Cell Lymphoma Predominantly Composed of Anaplastic Cells: A Frequently Misdiagnosed and Highly Aggressive Variant. (PubMed, Am J Surg Pathol)
This rare variant of ENKTL, characterized by the predominance of anaplastic cells and diffuse CD30 expression, exhibits high aggressiveness and should be differentiated from ALK-negative ALCL. Awareness of this uncommon variant is crucial in preventing misdiagnosis and ensuring the timely initiation of therapy.
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • NCAM1 (Neural cell adhesion molecule 1) • GZMB (Granzyme B) • IRF4 (Interferon regulatory factor 4)
|
TNFRSF8 positive • TNFRSF8 expression • ALK negative
4ms
Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real-world study. (PubMed, Cancer Med)
BV-based regimens could be a promising therapeutic option with remarkable effectiveness and moderate toxicity in treating Chinese lymphoma patients with CD30 expression.
Journal • Real-world evidence • Real-world
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive • TNFRSF8 expression
|
Adcetris (brentuximab vedotin)
4ms
SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas. (PubMed, Clin Lymphoma Myeloma Leuk)
Among the more successful strategies are the use of consolidative autologous stem cell transplant, the augmentation of CHOP with etoposide (CHOEP), and the use of brentuximab vedotin in CD30-positive PTCL. For patients with acute T-cell leukemia/lymphoma, the use of mogamulizumab-based therapy in the frontline setting may lead to advances in care. The true impact of these new-era therapies will only be elucidated as clinical practices incorporate the rapidly changing evidence.
Review • Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
etoposide IV • Adcetris (brentuximab vedotin) • Poteligeo (mogamulizumab-kpkc)
5ms
Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States. (PubMed, Clin Lymphoma Myeloma Leuk)
These real-world outcomes are consistent with ALCANZA results, demonstrating favorable outcomes with BV vs. OST in patients with CTCL previously treated with ≥1 systemic therapy.
Clinical data • Journal • HEOR • Real-world evidence • Real-world
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive • TNFRSF8 expression
|
methotrexate • Adcetris (brentuximab vedotin) • bendamustine • Poteligeo (mogamulizumab-kpkc) • Targretin oral (bexarotene oral)
5ms
PD-1 Blockade Combined with R-CHOP in Patients with Newly Diagnosed EBV-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Analysis (ASH 2023)
Longer follow-up is still warranted to confirm the long-term benefit, especially for patients with maintenance of PD-1 blockade. Still, we believe this therapeutic strategy can be regarded as a successful attempt at improving prognosis for pts with EBV+ DLBCL.
Retrospective data • PD(L)-1 Biomarker • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
PD-L1 expression • PD-L1 negative • TNFRSF8 positive
|
Rituxan (rituximab)
5ms
The Effect of Preemptive Rituximab Treatment in Patients with EBV Viremia after Solid Organ Transplantation on the Development of Post-Transplant Lymphoproliferative Disorder (ASH 2023)
The fact that peak EBV titer and duration of EBV viremia remain associated with PTLD in multivariate analyses suggests that the benefit of rituximab may be independent of the degree or duration of EBV viremia. A prospective analysis of factors such as area under the curve of EBV exposure, HLA status, T cell clonotype diversity, organ type, and immunosuppression type, is needed to better understand individual risks for improved selection of those who would benefit from preemptive rituximab.
Clinical • Post-transplantation
|
CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • IGH (Immunoglobulin Heavy Locus)
|
CD20 positive • TNFRSF8 positive
|
Rituxan (rituximab)
5ms
Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results (ASH 2023)
Pts ages 15–75 with CD30+ lymphomas refractory to brentuximab vedotin were enrolled...Each treatment cycle consisted of fludarabine/cyclophosphamide (days −5 to −3) followed by infusion (day 0) of the AFM13-precomplexed CB NK cells, cultured for 14 days as described above, and three weekly IV infusions of AFM13 (200 mg, days 7, 14 and 21)... CB-derived cytokine-induced memory-like NK cells precomplexed with AFM13 have excellent tolerability and activity for pts with heavily pretreated and refractory CD30+ lymphoma.
Clinical • IO biomarker
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • IL2 (Interleukin 2) • IL18 (Interleukin 18) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • CD48 (CD48 Molecule) • IL15 (Interleukin 15) • IL21 (Interleukin 21)
|
TNFRSF8 positive
|
cyclophosphamide • Adcetris (brentuximab vedotin) • fludarabine IV • acimtamig (AFM13)